Sara Santos1, Eduardo Dantas2, Filipe Veloso Gomes3,4, José Hugo Luz3,4, Nuno Vasco Costa3,4, Tiago Bilhim3,4, Filipe Calinas1, Américo Martins5, Élia Coimbra4. 1. Gastroenterology and Hepatology Department, Centro Hospitalar Universitário de Lisboa Central (CHULC), Lisbon, Portugal. 2. Gastroenterology and Hepatology Department, Centro Hospitalar de Setúbal, Setúbal, Portugal. 3. NOVA Medical School, Lisbon, Portugal. 4. Interventional Radiology Unit, Curry Cabral Hospital, Centro Hospitalar Universitário de Lisboa Central (CHULC), Lisbon, Portugal. 5. Surgery Department, Curry Cabral Hospital, Centro Hospitalar Universitário de Lisboa Central (CHULC), Lisbon, Portugal.
Abstract
BACKGROUND AND AIMS: Transjugular intrahepatic portosystemic shunt (TIPS) is used for decompressing clinically significant portal hypertension. The aims of this study were to evaluate clinical outcomes and adverse events associated with this procedure. METHODS: Retrospective single-center study including 78 patients submitted to TIPS placement between January 2015 and November 2018. Follow-up data were missing in 27 patients, and finally 51 patients were included in the study sample. Data collected from individual registries included demographics, comorbidities, laboratory results, complications, and clinical results according to the indication. RESULTS: Average pre-TIPS portosystemic pressure gradient decreased from 18.1 ± 5 to 6 ± 3 mm Hg after TIPS placement. Indications for TIPS were refractory ascites (63%, n = 49), recurrent or uncontrolled variceal bleeding (36%, n = 28), and Budd-Chiari syndrome (1.3%, n = 1). TIPS-related adverse events occurred in 29/51 (56.8%) patients, with hepatic encephalopathy (HE) in 21 (41%) patients, sepsis in 3, liver failure in 2, hemolytic anemia in 1, acute pulmonary edema in 1, and capsular perforation in 1 patient. Mean follow-up was 15.7 ± 15 months. First-month mortality was 11.7% (n = 6) (sepsis, n = 3; acute liver failure, n = 2; and recurrence of variceal bleeding, n = 1) and was significantly higher for patients with Child-Pugh >9 points (p = 0.01), model of end-stage liver disease (MELD) scores >19 (p = 0.02), and for patients with a history of HE before the procedure (p = 0.001). Older age (p = 0.006) and higher levels of creatinine (p = 0.008) were significantly higher in patients developing HE after TIPS. Ascites persisted in 21.2% (7/33 patients) and was more frequent in patients with lower baseline albumin levels (p = 0.003). Recurrent variceal bleeding occurred in 22% (n = 4/18 patients) and was more frequent in patients with lower baseline hemoglobin levels (p = 0.03). CONCLUSION: TIPS is effective in up to 80% of patients presenting with variceal bleeding or refractory ascites. Careful patient selection based on age and HE history may reduce adverse events after TIPS.
BACKGROUND AND AIMS: Transjugular intrahepatic portosystemic shunt (TIPS) is used for decompressing clinically significant portal hypertension. The aims of this study were to evaluate clinical outcomes and adverse events associated with this procedure. METHODS: Retrospective single-center study including 78 patients submitted to TIPS placement between January 2015 and November 2018. Follow-up data were missing in 27 patients, and finally 51 patients were included in the study sample. Data collected from individual registries included demographics, comorbidities, laboratory results, complications, and clinical results according to the indication. RESULTS: Average pre-TIPS portosystemic pressure gradient decreased from 18.1 ± 5 to 6 ± 3 mm Hg after TIPS placement. Indications for TIPS were refractory ascites (63%, n = 49), recurrent or uncontrolled variceal bleeding (36%, n = 28), and Budd-Chiari syndrome (1.3%, n = 1). TIPS-related adverse events occurred in 29/51 (56.8%) patients, with hepatic encephalopathy (HE) in 21 (41%) patients, sepsis in 3, liver failure in 2, hemolytic anemia in 1, acute pulmonary edema in 1, and capsular perforation in 1 patient. Mean follow-up was 15.7 ± 15 months. First-month mortality was 11.7% (n = 6) (sepsis, n = 3; acute liver failure, n = 2; and recurrence of variceal bleeding, n = 1) and was significantly higher for patients with Child-Pugh >9 points (p = 0.01), model of end-stage liver disease (MELD) scores >19 (p = 0.02), and for patients with a history of HE before the procedure (p = 0.001). Older age (p = 0.006) and higher levels of creatinine (p = 0.008) were significantly higher in patients developing HE after TIPS. Ascites persisted in 21.2% (7/33 patients) and was more frequent in patients with lower baseline albumin levels (p = 0.003). Recurrent variceal bleeding occurred in 22% (n = 4/18 patients) and was more frequent in patients with lower baseline hemoglobin levels (p = 0.03). CONCLUSION: TIPS is effective in up to 80% of patients presenting with variceal bleeding or refractory ascites. Careful patient selection based on age and HE history may reduce adverse events after TIPS.
Authors: Juan Carlos García-Pagán; Karel Caca; Christophe Bureau; Wim Laleman; Beate Appenrodt; Angelo Luca; Juan G Abraldes; Frederik Nevens; Jean Pierre Vinel; Joachim Mössner; Jaime Bosch Journal: N Engl J Med Date: 2010-06-24 Impact factor: 91.245
Authors: Virginia Hernández-Gea; Bogdan Procopet; Álvaro Giráldez; Lucio Amitrano; Candid Villanueva; Dominique Thabut; Luis Ibañez-Samaniego; Gilberto Silva-Junior; Javier Martinez; Joan Genescà; Christophe Bureau; Jonel Trebicka; Elba Llop; Wim Laleman; Jose Maria Palazon; Jose Castellote; Susana Rodrigues; Lise L Gluud; Carlos Noronha Ferreira; Rafael Barcelo; Nuria Cañete; Manuel Rodríguez; Arnulf Ferlitsch; Jose Luis Mundi; Henning Gronbaek; Manuel Hernández-Guerra; Romano Sassatelli; Alessandra Dell'Era; Marco Senzolo; Juan G Abraldes; Manuel Romero-Gómez; Alexander Zipprich; Meritxell Casas; Helena Masnou; Massimo Primignani; Aleksander Krag; Frederik Nevens; Jose Luis Calleja; Christian Jansen; Marie Angèle Robic; Irene Conejo; Maria-Vega Catalina; Agustin Albillos; Marika Rudler; Edilmar Alvarado; Maria Anna Guardascione; Marcel Tantau; Jaime Bosch; Ferran Torres; Juan Carlos Garcia-Pagán Journal: Hepatology Date: 2018-12-10 Impact factor: 17.425
Authors: Felix Piecha; Ulf K Radunski; Ann-Kathrin Ozga; David Steins; Andreas Drolz; Thomas Horvatits; Clemens Spink; Harald Ittrich; Daniel Benten; Ansgar W Lohse; Christoph Sinning; Johannes Kluwe Journal: JHEP Rep Date: 2019-05-10
Authors: Dhiraj Tripathi; Adrian J Stanley; Peter C Hayes; Simon Travis; Matthew J Armstrong; Emmanuel A Tsochatzis; Ian A Rowe; Nicholas Roslund; Hamish Ireland; Mandy Lomax; Joanne A Leithead; Homoyon Mehrzad; Richard J Aspinall; Joanne McDonagh; David Patch Journal: Gut Date: 2020-02-29 Impact factor: 23.059